Accessibility StatementSkip Navigation NEW YORK, Sept. 10, 2025 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Dow Inc. (NYSE: DOW) between January 30, 2025 and July 23, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 28, 2025. Laurence Rosen, Esq.Phillip Kim, Es ...

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Dow Inc. (NYSE: DOW) between January 30, 2025 and July 23, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 28, 2025. SO WHAT: If you purchased Dow Inc. securities during the Class Period y ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased CTO Realty Growth, Inc. securities between February 18, 2021, and June 24, 2025, of the upcoming lead plaintiff deadline on October 7, 2025 [1]. Group 1: Class Action Details - Investors who purchased CTO Realty securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by October 7, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that CTO Realty Growth made false and misleading statements regarding the sustainability of its dividends and the profitability of its Ashford Lane property [5]. - It is claimed that the company's business and financial prospects were overstated, leading to investor damages when the true information became public [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025, about the lead plaintiff deadline of October 6, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Altimmune securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by October 6, 2025 [2]. - The lawsuit claims that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, failing to meet a key statistical significance marker for fibrosis reduction [4]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Lineage, Inc. common stock about the September 30, 2025 lead plaintiff deadline for a class action lawsuit related to the company's July 2024 IPO [1]. Group 1: Class Action Details - Investors who purchased Lineage common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by September 30, 2025 [3]. - The lawsuit claims that the registration statement was false and/or misleading, failing to disclose significant issues affecting Lineage's business operations and financial results [5]. Group 2: Allegations Against Lineage - The lawsuit alleges that Lineage experienced a sustained weakening in customer demand due to increased cold-storage supply and destocking of excessive inventory by customers [5]. - It is claimed that Lineage implemented unsustainable price increases prior to the IPO, which could not be maintained in the face of weakening demand [5]. - The company reportedly could not counteract adverse trends through operational efficiencies or competitive advantages, leading to stagnant or falling revenue, occupancy rates, and rent prices [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Rosen Law Firm has been recognized for its leadership in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased SelectQuote, Inc. securities between September 9, 2020, and May 1, 2025, of the upcoming lead plaintiff deadline on October 10, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased SelectQuote securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3]. Group 2: Allegations Against SelectQuote - The lawsuit alleges that SelectQuote made false and misleading statements, including directing Medicare beneficiaries to plans that compensated SelectQuote rather than providing unbiased comparisons [4]. - It is claimed that SelectQuote received illegal kickbacks to steer Medicare beneficiaries to certain insurers, which resulted in non-compliance with applicable laws and regulations [4]. - The lawsuit asserts that the misleading statements about SelectQuote's business operations led to investor damages when the true details became public [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Tronox Holdings plc common stock during the specified Class Period, indicating potential legal issues surrounding the company's financial disclosures and performance [1][5]. Group 1: Lawsuit Details - The class action lawsuit is filed for purchasers of Tronox common stock between February 12, 2025, and July 30, 2025, inclusive [1]. - The lawsuit claims that Tronox provided misleading statements regarding its ability to forecast demand for its products, leading to a decline in sales and increased costs, which ultimately affected revenue projections [5]. Group 2: Investor Information - Investors who purchased Tronox common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Spectrum Pharmaceuticals, Inc. during the specified class period of the upcoming lead plaintiff deadline on September 24, 2025, as the lead plaintiff process has been reopened by the Court [1]. Group 1: Class Action Details - Investors who bought Spectrum Pharmaceuticals common stock between May 12, 2022, and September 22, 2022, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed against Spectrum Pharmaceuticals, and interested parties can join by contacting the law firm [3][5]. - The lawsuit alleges that Spectrum made false or misleading statements regarding its PINNACLE Study, which involved the drug poziotinib for lung cancer treatment, leading to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and has recovered hundreds of millions for investors over the years [4]. Group 3: Class Certification Status - No class has been certified yet, meaning investors are not represented by counsel unless they retain one, and they can choose to remain absent from the class at this stage [6].

Core Viewpoint - A class action lawsuit has been filed against Dow Inc. for alleged misleading statements regarding its financial condition and ability to manage macroeconomic challenges during the Class Period from January 30, 2025, to July 23, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Dow Inc. overstated its ability to handle macroeconomic and tariff-related challenges, which negatively impacted its financial flexibility and dividend support [5]. - It is alleged that Dow Inc. failed to disclose the true extent of competitive pressures, declining global sales, and product oversupply, leading to materially false public statements [5]. - Investors are encouraged to join the class action to seek compensation without upfront costs through a contingency fee arrangement [2][3]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors and has a strong track record in recovering significant settlements [4]. - Investors are advised to select qualified legal counsel with proven experience in similar cases to ensure effective representation [4]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must file a motion by October 28, 2025, to represent the class in the lawsuit [1][3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PubMatic, Inc. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from February 27, 2025, to August 11, 2025, and the lead plaintiff deadline is October 20, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [3]. Group 3: Case Allegations - The lawsuit alleges that PubMatic made false and misleading statements regarding its business operations, particularly related to a top demand side platform buyer shifting clients to a new platform, resulting in reduced ad spend and revenue [4]. - The misleading statements led to investor damages when the true details were revealed [4].